NOVEL METHOD FOR DETECTING TELOMERASE

检测端粒酶的新方法

• 批准号: 2717553
• 负责人: JAN TRNOVSKY
• 金额: $ 10万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-07-01 至 1998-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2717553
• 关键词: cell line; enzyme activity; flow cytometry; fluorescent in situ hybridization; gel; messenger RNA; method development; microcapsule; neoplastic cell; telomerase

In Phase I research, we propose to combine gel microdrop (GMD) single cell encapsulation and flow cytometry to distinguish telomerase positive cells present in a heterogenous population. Detection of telomerase expression at the mRNA level will permit discrimination of previously undetectable tumor cells both in blood and in benign tissues. It can also be used as an informative marker of residual disease for patients undergoing chemotherapy. Since telomerase positive cells are present within a heterogenous population, an in situ assay capable of precisely detecting and isolating telomerase labeled cells would be broadly applicable for future studies in clinical oncology. PROPOSED COMMERCIAL APPLICATION The ability to detect small sub-populations of cells which are positive for telomerase activity would be a significant advance in clinical diagnostics. Early detection of cancer would improve health care.

在第一阶段的研究中，我们建议将凝胶微旋转（GMD）单一组合 细胞封装和流式细胞术以区分端粒酶阳性 细胞存在于异源种群中。检测端粒酶 mRNA水平的表达将允许歧视以前 血液和良性组织中的无法检测到的肿瘤细胞。 它可以 也可以用作患者残留疾病的信息标记 接受化学疗法。 由于存在端粒酶阳性细胞 在异质种群中，能够精确的原位测定 检测和隔离端粒酶标记的细胞将广泛 适用于未来的临床肿瘤学研究。 拟议的商业应用 检测阳性细胞的小亚种群的能力 对于端粒酶活性，在临床上将是一个重大进步 诊断。 早期发现癌症将改善医疗保健。